Advertisement

Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer

Abstract

Aims and background. To ascertain the value of the detection of urinary modified nucleosides in the early diagnosis and prognostic monitoring of urothelial bladder cancer.
Methods. One hundred seventeen patients with urothelial bladder carcinoma and 66 healthy volunteers were included in the study. High-performance liquid chromatography/ electrospray ionization quadrupole time-of-flight mass spectrometry (HPLC/ESI-Q-TOF-MS) was used to measure the levels of urinary modified nucleosides in the bladder cancer and control groups. Postoperative monitoring was done every 3 months in patients with noninvasive carcinoma; 85 patients attended the 1-year follow-up visit.
Results. The levels of m1A, ac4C, O6-MeG and 1-MeI were significantly higher in cases than controls (P >0.05). The highest sensitivity (92.45%) and specificity (87.50%) were obtained when 1-MeI detection was combined with m1A detection. The m1A and 1-MeI levels 3 months after operation in both patient groups were significantly lower than the preoperative levels (P >0.01). The no-recurrence group subsequently maintained low levels, but in the recurrence group the levels rose again almost to preoperative values. At 6, 9 and 12 months after operation, the m1A and 1-MeI levels of the recurrence group were higher than those of the no-recurrence group and the control group (P >0.01).
Conclusions. Urinary modified nucleosides might become novel tumor markers that will facilitate the clinical management and will be helpful in the diagnosis and followup of urothelial bladder cancer. m1A and 1-MeI appear to be most promising for clinical use and be worthy of further study in the near future.

Tumori 2014; 100(6): 660 - 666

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1778.19274

Authors

Yu-Rui Zhang, Lei Shi, Hui Wu, Dong-Dong Tang, Shao-Min Wang, Hong-Min Liu, Li-Rong Zhang, Dong-Kui Song

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Zhang, Yu-Rui [PubMed] [Google Scholar]
    Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Shi, Lei [PubMed] [Google Scholar]
    Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Wu, Hui [PubMed] [Google Scholar]
    Department of Urology, the First People’s Hospital of Zhengzhou, Zhengzhou, China
  • Tang, Dong-Dong [PubMed] [Google Scholar]
    Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Wang, Shao-Min [PubMed] [Google Scholar]
    Department of Chemistry, Zhengzhou University, Zhengzhou, China
  • Liu, Hong-Min [PubMed] [Google Scholar]
    School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, China
  • Zhang, Li-Rong [PubMed] [Google Scholar]
    Department of Pharmacology, School of Basic Medicine, Zhengzhou University, Zhengzhou, China
  • Song, Dong-Kui [PubMed] [Google Scholar]
    Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.